Article Details
Retrieved on: 2021-04-24 12:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Finally, Morgan Stanley upped their target price on Alnylam Pharmaceuticals from $203.00 to $206.00 and gave the company an "overweight" rating in ...
Article found on: www.marketbeat.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here